Novartis | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 38.75B 4.31B 2024-12
Alcon AG USD 2.28B 178M 2024-12
Almirall EUR 274.01M 14.41M 2024-06
Amgen USD 23.1B 2.79B 2024-12
AstraZeneca USD 27.87B 1.94B 2024-12
Autolus Therapeutics Ltd 52.47M 11.57M 2024-09
Bayer EUR 28.95B 3.9B 2024-12
Biogen USD 5.53B 103.8M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
Fresenius EUR 6.09B 2.19B 2024-12
Fresenius Medical Care EUR 5.66B 228.94M 2024-12
Galapagos EUR 335.08M 16.15M 2024-12
Genmab DKK 5.31B 723M 2024-12
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 21.7B 238M 2024-12
GRIFOLS EUR 2.16B 199.43M 2024-12
Hikma Pharmaceutical USD 1.38B 41M 2024-06
J&J USD 50.32B 1.44B 2024-12
Lonza CHF 3.58B 970M 2024-12
Merck EUR 10.46B 532M 2024-09
Merck USD 28.42B 1.17B 2024-12
Novartis USD 28.69B 560M 2024-12
Novartis USD 28.69B 560M 2024-12
Novo Nordisk 208.36B 20.45B 2024-09
Orion EUR 273.4M 130.4M 2024-12
Pfizer USD 43B 216M 2024-12
Philips EUR 8.15B 615M 2024-12
Recordati EUR 906.69M 19.47M 2024-09
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 30.03B 5.82B 2024-06
UCB EUR 3.53B 731M 2024-12



Novartis Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.